AU2020276595B2 - Antifungal Agents for Candida Auris Decolonization - Google Patents

Antifungal Agents for Candida Auris Decolonization

Info

Publication number
AU2020276595B2
AU2020276595B2 AU2020276595A AU2020276595A AU2020276595B2 AU 2020276595 B2 AU2020276595 B2 AU 2020276595B2 AU 2020276595 A AU2020276595 A AU 2020276595A AU 2020276595 A AU2020276595 A AU 2020276595A AU 2020276595 B2 AU2020276595 B2 AU 2020276595B2
Authority
AU
Australia
Prior art keywords
compound
candida auris
formula
iia
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020276595A
Other languages
English (en)
Other versions
AU2020276595A1 (en
Inventor
David A. ANGULO GONZALEZ
Stephen Andrew BARAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
SCYNEXIS Inc
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCYNEXIS Inc, Scynexis Inc filed Critical SCYNEXIS Inc
Publication of AU2020276595A1 publication Critical patent/AU2020276595A1/en
Application granted granted Critical
Publication of AU2020276595B2 publication Critical patent/AU2020276595B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2020276595A 2019-05-16 2020-05-12 Antifungal Agents for Candida Auris Decolonization Active AU2020276595B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16
US62/849,019 2019-05-16
PCT/US2020/032547 WO2020232037A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Publications (2)

Publication Number Publication Date
AU2020276595A1 AU2020276595A1 (en) 2021-12-09
AU2020276595B2 true AU2020276595B2 (en) 2025-12-04

Family

ID=70861571

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020276595A Active AU2020276595B2 (en) 2019-05-16 2020-05-12 Antifungal Agents for Candida Auris Decolonization

Country Status (14)

Country Link
US (1) US20220211684A1 (https=)
EP (1) EP3968986A1 (https=)
JP (2) JP7770191B2 (https=)
KR (1) KR20220009416A (https=)
CN (1) CN113905733A (https=)
AU (1) AU2020276595B2 (https=)
BR (1) BR112021022876A2 (https=)
CA (1) CA3140637A1 (https=)
EA (1) EA202193146A1 (https=)
IL (1) IL288165B1 (https=)
MA (1) MA55958A (https=)
MX (1) MX2021013899A (https=)
TW (2) TWI881977B (https=)
WO (1) WO2020232037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191077A1 (en) * 2017-04-10 2018-10-18 Scynexis, Inc. Antifungal agents used in combination
WO2018213641A1 (en) * 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
MA43825A (fr) * 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
US20220117948A1 (en) * 2019-01-30 2022-04-21 Scynexis, Inc. Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191077A1 (en) * 2017-04-10 2018-10-18 Scynexis, Inc. Antifungal agents used in combination
WO2018213641A1 (en) * 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JUNEJA, D. et al., European Congress of Clinical Microbiology and Infectious Diseases, 13-16 April 2019. Poster L0028 *
LARKIN, E. et al., 'The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor *
RAIESI, O. et al., 'Candida auris: A New Emerging Fungal Monster', Archives of Clinical Infectious Diseases. 2019, Vol. 14, No. 2, e70741, pp. 1-6, Published April 2019 *

Also Published As

Publication number Publication date
CN113905733A (zh) 2022-01-07
TW202110441A (zh) 2021-03-16
EA202193146A1 (ru) 2022-02-11
US20220211684A1 (en) 2022-07-07
CA3140637A1 (en) 2020-11-19
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
KR20220009416A (ko) 2022-01-24
EP3968986A1 (en) 2022-03-23
AU2020276595A1 (en) 2021-12-09
TWI881977B (zh) 2025-05-01
WO2020232037A1 (en) 2020-11-19
JP2025118765A (ja) 2025-08-13
BR112021022876A2 (pt) 2022-04-12
JP2022532734A (ja) 2022-07-19
TW202602460A (zh) 2026-01-16
JP7770191B2 (ja) 2025-11-14
MA55958A (fr) 2022-03-23
IL288165A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
JP2025118765A (ja) カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤
US20250248983A1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
EA048874B1 (ru) Противогрибковые агенты для деколонизации candida auris
HK40067174A (zh) 用於消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂
ES3055272T3 (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
EA051506B1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций
HK40066679A (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40066679B (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40062347A (en) Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION

FGA Letters patent sealed or granted (standard patent)